AMERSA

AMERSA

Call Us: (401) 615-4047 | Contact Us AMERSA on Twitter AMERSA on LinkedIn AMERSA on BlueSky

Make a Donation Pay a Past-Due Balance Join Our Mailing List
  • About
    • What is AMERSA
    • Board of Directors
    • Donate to AMERSA
    • Contact Us
  • Membership
    • Get to Know AMERSA
    • Join / Renew
    • Who We Are
    • Member Center
    • Special Interest Groups
    • Career Opportunities
    • Professional & Academic Advancement Opps
  • Conference
    • Annual Conference
    • Conference Sponsorship
    • Conference Exhibitor Information
    • Policy and Procedures for AMERSA Events
    • 2024 Conference Materials
    • Past Conference Resources
  • Journal
    • Journal Home
    • About Us
    • Member Access to Journal
    • Author Instructions and Submission
    • SAj Blog
    • SAj Annual Awards
    • SAj Editorial Scholar Program
  • Advocacy
    • AMERSA Advocacy
    • Position Statements
    • Submit a Position Statement
    • Letters of Support
    • Public Comments
  • Sustainability
    • Initiatives
    • Resources
  • Education
    • AMERSA Podcast Series
    • AMERSA Webinars
    • Core Competencies – AMERSA in the 21st Century
    • Resources
  • Awards
    • AMERSA Awards
    • Current Award Winners
    • Past Award Winners

Public Comments

AMERSA Public Comment to DEA Buprenorphine Telehealth Regulations

AMERSA supports the DEA’s efforts to update federal regulations related to buprenorphine telehealth. For the last three years during the COVID-19 pandemic and associated public health emergency, telehealth has been used effectively and often exclusively by patients to receive buprenorphine for opioid use disorder (OUD) treatment. Patients and providers are highly satisfied with this treatment model, which has shown high treatment retention, treatment follow up, and reductions in overdose deaths. 

To maintain and improve OUD treatment access and reduce overdose deaths, we are urging the DEA to 1) remove the 30-day in person visit requirement and 2) maintain audio-only telehealth for buprenorphine treatment as a permissible primary modality for the delivery of buprenorphine telehealth. We recommend these actions be taken through the allowances granted by the Opioid Public Health Emergency, pursuant to section 319 of the Public Health Service Act.

AMERSA Public Comment to SAMHSA Proposed Methadone Regulation Changes
AMERSA applauds SAMHSA’s efforts to update federal regulations related to Medications for the Treatment of Opioid Use Disorder 42 Code of Federal Regulations (CFR) Part 8 Notification of Proposed Rule Making (NPRM). As an organization deeply committed to improving health and well-being among communities with substance use disorders, we have provided detailed comments on several topics related to the NPRM, as well as making several added considerations that are currently not included. 

AMERSA Solidarity Statement 6/11/20

Copyright © 2025
Site by: web360